Page 23 - EASL POSTGRADUATE COURSE

References
[1] Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and

elevated liver enzymes. Hepatology 2006;44:865-873.
[2] Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of

clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
[3] Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty

liver disease. Gastroenterology 2005;128:1898-1906.
[4] Bedossa P, Consortium FP. Utility and appropriateness of the fatty liver inhibition of progression

(FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of
nonalcoholic fatty liver disease. Hepatology 2014;60:565-575.
[5] Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation
in clinical research. Semin Liver Dis 2012;32:3-13.
[6] Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic
steatohepatitis. Hepatology 2011;54:344-353.
[7] Kleiner DE, Brunt EM,Van Natta M, et al. Design and validation of a histological scoring system
for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
[8] Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific
mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014.
[9] Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis:
interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874-
1882.

The International Liver Congress™ 2015 • Vienna, Austria • April 22–23, 2015 23